跳至主要内容
临床试验/NCT00898417
NCT00898417已完成不适用

Development of a Serum Proteomic Classifier for the Prediction of Benefit From Bevacizumab in Combination With Carboplatin and Paclitaxel

ECOG-ACRIN Cancer Research Group0 个研究点目标入组 90 人开始时间: 2008年3月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90
主要终点
Survival

研究概览

简要总结

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment.

PURPOSE: This laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.

详细描述

OBJECTIVES:

Primary

  • To develop a serum proteomic classifier using matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry analysis of blood samples from patients with non-squamous cell non-small cell lung cancer to predict benefit, in terms of survival and time to progression, from treatment with bevacizumab in combination with carboplatin and paclitaxel.

Secondary

  • To better quantitate candidate biomarkers by using more advanced mass spectrometric technologies, including multiple-reaction monitoring and heavy-labeled peptides.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Survival

时间窗: 1 day

次要结局

未报告次要终点

研究者

发起方
ECOG-ACRIN Cancer Research Group
申办方类型
Network
责任方
Sponsor

相似试验

Biomarker Study of Blood Samples From Patients With... | 临床试验